WASHINGTON, Jan 14 (Reuters) - The U.S. Food and Drug Administration appears skeptical that data submitted by Johnson & Johnson proves its anticoagulant Xarelto is effective in reducing the risk of further heart problems in patients who have recently suffered a heart attack.
The agency questioned the way in which J&J analyzed clinical trial data, and said there was no convincing proof the drug confers significant benefit or fills an unmet medical need, given that there are other therapies on the market.
The review was posted on the FDA's website on Tuesday, two days ahead of a meeting of outside experts who will discuss the drug, also known as rivaroxaban, and recommend whether it should be approved.
Xarelto is already used to treat and prevent deep vein thrombosis and pulmonary embolisms and to reduce the risk of stroke and blood clots in patients with an irregular heart beat that is not caused by heart problems.
Now the company is hoping it will also be approved for patients with acute coronary syndrome (ACS), an umbrella term covering any condition brought on by a sudden, reduced blood flow to the heart, including heart attack and chest pain.
Some analysts are doubtful.
"Based on our review of this material, we continue to have low expectation of approval," Larry Biegelsen, an analyst at Wells Fargo Securities, said in a research note. However, he expects sales of the drug to rise to $1.2 billion in 2015 from an estimated $703 million in 2013 based on the indications for which it is approved.
"We expect the ACS potential to be modest even if approved," he said.
J&J originally filed for approval of Xarelto in ACS at the end of 2011. The FDA rejected the application, saying efficacy data was not strong enough to support approval. The company provided additional information but the FDA once again declined to approve the drug, prompting J&J to appeal the decision.
The FDA denied the appeal but said limiting the duration of use to one month might be a pathway forward because efficacy was more evident and the risk of bleeding, a side effect of the drug, was lower during this period. J&J filed a new application seeking a treatment duration of 90 days.
The FDA's latest review suggests the agency remains skeptical.
"It is unclear how to choose the metric for determining when the benefit of rivaroxaban is greatest," the review found. "Not only does the effect of rivaroxaban not appear to be greater earlier, but an effect in the first 90 days or so is not apparent at all."
Dr. Paul Burton, vice president of clinical development at Janssen Research and Development, a J&J unit, defended the drug, saying the company believes that when added to standard treatments it "delivers a strong incremental benefit by significantly reducing the risk of cardiovascular events, including death, at a time when patients are at the highest risk."
The FDA's review also questioned whether the benefit of the drug outweighs the heightened risk of bleeding since two other drugs, Eli Lilly & Co's Effient and AstraZeneca Plc's Brilinta, are currently approved for ACS.
J&J's proposed prescribing information would warn that treatment in combination with the Effient, known also as prasugrel, and Brilinta, also known as ticagrelor, has not been studied and is not recommended because of the risk of bleeding.
Xarelto would therefore only be available as an add-on to Bristol-Myers Squibb Co's antiplatelet Plavix, or clopidogrel.
"There are no data demonstrating that ACS patients treated with clopidogrel plus rivaroxaban will have superior outcomes compared to treatment with prasugrel or ticagrelor," the review said. "So rivaroxaban does not provide therapy for an unmet medical need."
And while treatment for a limited duration "has an intuitive appeal," the review said, "the task for the analyses of the effect of rivaroxaban over time is not to pick a time period in which the benefit-risk is acceptable."
Our 2024 Coverage Needs You
It's Another Trump-Biden Showdown — And We Need Your Help
The Future Of Democracy Is At Stake
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
The 2024 election is heating up, and women's rights, health care, voting rights, and the very future of democracy are all at stake. Donald Trump will face Joe Biden in the most consequential vote of our time. And HuffPost will be there, covering every twist and turn. America's future hangs in the balance. Would you consider contributing to support our journalism and keep it free for all during this critical season?
HuffPost believes news should be accessible to everyone, regardless of their ability to pay for it. We rely on readers like you to help fund our work. Any contribution you can make — even as little as $2 — goes directly toward supporting the impactful journalism that we will continue to produce this year. Thank you for being part of our story.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
It's official: Donald Trump will face Joe Biden this fall in the presidential election. As we face the most consequential presidential election of our time, HuffPost is committed to bringing you up-to-date, accurate news about the 2024 race. While other outlets have retreated behind paywalls, you can trust our news will stay free.
But we can't do it without your help. Reader funding is one of the key ways we support our newsroom. Would you consider making a donation to help fund our news during this critical time? Your contributions are vital to supporting a free press.
Contribute as little as $2 to keep our journalism free and accessible to all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you'll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.